Recent Updates
Recently added Catalysts

CCX140-B

Phase 3

Diabetic Nephropathy | Small molecule | Metabolic |Amgen Inc.|Trials Updated: Mar 13, 2025

CCX140-B development status

Highest phase Phase 3 run by Beijing Minhai Biotechnology Co., Ltd (NCT02003313)
Phase scored for AMGNPhase 2
Registered trials 9 across 5 sponsors since Dec 2009

CCX140-B target and mechanism

ModalitySmall molecule

Also known as Group B, Group C, Group D

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindPLACEBO_CONTROLLEDDMC
Total Trials4
Total Enrollment557

FDA Designations

No designations recorded

CCX140-B clinical trials

CCX140-B · 4 trials · 5 indications

Phase 2 4
NCT03536754A Study of CCX140-B in Subjects With FSGSFSGS
COMPLETED46 Analytics
NCT01447147A Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects With Diabetic NephropathyDiabetic Nephropathy
COMPLETED332 Analytics
NCT01440257A Study to Evaluate the Effect of CCX140-B on Urinary Albumin Excretion in Subjects With Type 2 Diabetes and AlbuminuriaDiabetic Nephropathy
COMPLETED20 Analytics
NCT01028963A Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects With Type 2 Diabetes MellitusType 2 Diabetes Mellitus
COMPLETED159 Analytics
PHASE2COMPLETED
A Study of CCX140-B in Subjects With FSGS
FSGS
NCT0353675446
Unlock trial analytics
PHASE2COMPLETED
A Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects With Diabetic Nephropathy
Diabetic Nephropathy
NCT01447147332
Unlock trial analytics
PHASE2COMPLETED
A Study to Evaluate the Effect of CCX140-B on Urinary Albumin Excretion in Subjects With Type 2 Diabetes and Albuminuria
Diabetic Nephropathy
NCT0144025720
Unlock trial analytics
PHASE2COMPLETED
A Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects With Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
NCT01028963159
Unlock trial analytics

Study Endpoints

Primary Endpoints

Change From Baseline in UPCR at Week 12
Baseline to Week 12

Least squared mean ratio of UPCR (Urine protein g:creatinine g) compared to baseline at Week 12 in the ITT population. ITT- Intent to treat

Number of Participants of Treatment-emergent AEs (TEAE), TEAEs Leading to Study Withdrawal, and Serious Adverse Events (SAEs)
Baseline to Week 12, and Week 12 to Week 24

TEAEs leading to study withdrawal means study drug discontinuation in this endpoint.

Change From Baseline in Activated Partial Thromboplastin Time
Baseline to Week 12 (double-blind treatment period) and Week 12 to Week 24 (open-label extension)

Normal Range: 23.9 - 40.0

Change From Baseline in Plasma Alanine Aminotransferase
Baseline to Week 12 (double-blind treatment period) and Week 12 to Week 24 (open-label extension)

Normal Range: 6 - 41 U/L

Change From Baseline in Plasma Alkaline Phosphatase
Baseline to Week 12 (double-blind treatment period) and Week 12 to Week 24 (open-label extension)
Change From Baseline in Plasma Amylase
Baseline to Week 12 (double-blind treatment period) and Week 12 to Week 24 (open-label extension)

Normal range: 22-123 U/L

Change From Baseline in Plasma Aspartate Aminotransferase
Baseline to Week 12 (double-blind treatment period) and Week 12 to Week 24 (open-label extension)

Normal range : 9-34 U/L

Change From Baseline in Plasma Bicarbonate
Baseline to Week 12 (double-blind treatment period) and Week 12 to Week 24 (open-label extension)

Normal range: 21-33 mmol/L

Change From Baseline in Plasma Bilirubin
Baseline to Week 12 (double-blind treatment period) and Week 12 to Week 24 (open-label extension)

Normal range: 0.1-1.10 mg/dL

Change From Baseline in Plasma C Reactive Protein
Baseline to Week 12 (double-blind treatment period) and Week 12 to Week 24 (open-label extension)

Normal range: 0.0-3.0 mg/L

Change From Baseline in Plasma Calcium
Baseline to Week 12 (double-blind treatment period) and Week 12 to Week 24 (open-label extension)

Normal range: 8.5-10.5 mg/dL

Change From Baseline in Plasma Chloride
Baseline to Week 12 (double-blind treatment period) and Week 12 to Week 24 (open-label extension)

Normal range: 95-110 mmol/L

Change From Baseline in Plasma Cholesterol
Baseline to Week 12 (double-blind treatment period) and Week 12 to Week 24 (open-label extension)

Normal range: 100-200 mg/dL

Change From Baseline in Plasma Creatine Kinase
Baseline to Week 12 (double-blind treatment period) and Week 12 to Week 24 (open-label extension)

Normal range: 23-210 U/L

Change From Baseline in Plasma Creatinine
Baseline to Week 12 (double-blind treatment period) and Week 12 to Week 24 (open-label extension)

Normal range: 0.62-1.44 mg/dL

Change From Baseline in Plasma Cystatin C
Baseline to Week 12 (double-blind treatment period) and Week 12 to Week 24 (open-label extension)

Normal range: 0.53-0.95 mg/L

Change From Baseline in Plasma Direct Bilirubin
Baseline to Week 12 (double-blind treatment period) and Week 12 to Week 24 (open-label extension)
Change From Baseline in Plasma Glucose
Baseline to Week 12 (double-blind treatment period) and Week 12 to Week 24 (open-label extension)
Change From Baseline in Plasma HDL Cholesterol
Baseline to Week 12 (double-blind treatment period) and Week 12 to Week 24 (open-label extension)

HDL -High-density lipoprotein

Change From Baseline in Plasma Indirect Bilirubin
Baseline to Week 12 (double-blind treatment period) and Week 12 to Week 24 (open-label extension)
Change From Baseline in Plasma LDL Cholesterol
Baseline to Week 12 (double-blind treatment period) and Week 12 to Week 24 (open-label extension)

LDL - Low-density lipoprotein

Change From Baseline in Lactate Dehydrogenase
Baseline to Week 12 (double-blind treatment period) and Week 12 to Week 24 (open-label extension)
Change From Baseline in Plasma Pancreatic Lipase
Baseline to Week 12 (double-blind treatment period) and Week 12 to Week 24 (open-label extension)
Change From Baseline in Plasma Magnesium
Baseline to Week 12 (double-blind treatment period) and Week 12 to Week 24 (open-label extension)
Change From Baseline in Plasma Phosphate
Baseline to Week 12 (double-blind treatment period) and Week 12 to Week 24 (open-label extension)
Change From Baseline in Plasma Potassium
Baseline to Week 12 (double-blind treatment period) and Week 12 to Week 24 (open-label extension)
Change From Baseline in Plasma Protein
Baseline to Week 12 (double-blind treatment period) and Week 12 to Week 24 (open-label extension)
Change From Baseline in Prothrombin Intl. Normalised Ratio
Baseline to Week 12 (double-blind treatment period) and Week 12 to Week 24 (open-label extension)
Change From Baseline in Prothrombin Time
Baseline to Week 12 (double-blind treatment period) and Week 12 to Week 24 (open-label extension)
Change From Baseline in Plasma Sodium
Baseline to Week 12 (double-blind treatment period) and Week 12 to Week 24 (open-label extension)
Change From Baseline in Plasma Triglycerides
Baseline to Week 12 (double-blind treatment period) and Week 12 to Week 24 (open-label extension)
Change From Baseline in Plasma Urate
Baseline to Week 12 (double-blind treatment period) and Week 12 to Week 24 (open-label extension)
Change From Baseline in Plasma Urea Nitrogen
Baseline to Week 12 (double-blind treatment period) and Week 12 to Week 24 (open-label extension)
Change From Baseline in Basophils
Baseline to Week 12 (double-blind treatment period) and Week 12 to Week 24 (open-label extension)
Change From Baseline in Basophils/Leukocytes
Baseline to Week 12 (double-blind treatment period) and Week 12 to Week 24 (open-label extension)
Change From Baseline in Eosinophils
Baseline to Week 12 (double-blind treatment period) and Week 12 to Week 24 (open-label extension)
Change From Baseline in Eosinophils/Leukocytes
Baseline to Week 12 (double-blind treatment period) and Week 12 to Week 24 (open-label extension)
Change From Baseline in Erythrocyte Mean Corpuscular HGB Concentration
Baseline to Week 12 (double-blind treatment period) and Week 12 to Week 24 (open-label extension)

HGB - Hemoglobin

Change From Baseline in Erythrocyte Mean Corpuscular Hemoglobin
Baseline to Week 12 (double-blind treatment period) and Week 12 to Week 24 (open-label extension)
Change From Baseline in Erythrocyte Mean Corpuscular Volume
Baseline to Week 12 (double-blind treatment period) and Week 12 to Week 24 (open-label extension)
Change From Baseline in Erythrocytes
Baseline to Week 12 (double-blind treatment period) and Week 12 to Week 24 (open-label extension)
Change From Baseline in Hematocrit
Baseline to Week 12 (double-blind treatment period) and Week 12 to Week 24 (open-label extension)
Change From Baseline in Hemoglobin
Baseline to Week 12 (double-blind treatment period) and Week 12 to Week 24 (open-label extension)
Change From Baseline in Leukocytes
Baseline to Week 12 (double-blind treatment period) and Week 12 to Week 24 (open-label extension)
Change From Baseline in Lymphocytes
Baseline to Week 12 (double-blind treatment period) and Week 12 to Week 24 (open-label extension)
Change From Baseline in Lymphocytes/Leukocytes
Baseline to Week 12 (double-blind treatment period) and Week 12 to Week 24 (open-label extension)
Change From Baseline in Monocytes/Leukocytes
Baseline to Week 12 (double-blind treatment period) and Week 12 to Week 24 (open-label extension)
Change From Baseline in Neutrophils
Baseline to Week 12 (double-blind treatment period) and Week 12 to Week 24 (open-label extension)
Change From Baseline in Neutrophils/Leukocytes
Baseline to Week 12 (double-blind treatment period) and Week 12 to Week 24 (open-label extension)
Change From Baseline in Platelets
Baseline to Week 12 (double-blind treatment period) and Week 12 to Week 24 (open-label extension)
Change From Baseline in Reticulocytes/Erythrocytes
Baseline to Week 12 (double-blind treatment period) and Week 12 to Week 24 (open-label extension)
Change From Baseline in Urine Albumin
Baseline to Week 12 (double-blind treatment period) and Week 12 to Week 24 (open-label extension)
Change From Baseline in Urine Creatinine
Baseline to Week 12 (double-blind treatment period) and Week 12 to Week 24 (open-label extension)
Change From Baseline in Urine Protein
Baseline to Week 12 (double-blind treatment period) and Week 12 to Week 24 (open-label extension)
Subject incidence of adverse events
Up to 365 days

The primary objective of this study is to evaluate the safety and tolerability of CCX140-B in subjects with diabetic nephropathy.

Change from baseline in 24-hour urinary albumin excretion
84 days

The primary efficacy objective of this study is to evaluate the effect of CCX140-B treatment on urinary albumin excretion by measuring change from baseline in 24-hour urinary albumin excretion.

Secondary Endpoints

Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Week 12 and Week 24
Baseline to Week 12 (double-blind treatment period) and Week 12 to Week 24 (open-label extension)
Proportion of Subjects Achieving Complete or Partial Renal Remission at Week 12 and Week 24
Endpoint at Week 12 for Double-Blind Treatment Period and Endpoint at Week 24 for Open-Label Extension
Change from baseline in first morning urinary albumin:creatinine ratio (ACR)
Up to 365 days
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingTRIPLE
ModelSEQUENTIAL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
Group APLACEBO_COMPARATORPlacebo (N=10)
Group BEXPERIMENTALCCX140-B 5 mg once daily (N=10)
Group CEXPERIMENTALCCX140-B 10 mg twice daily (N=10)
Group DEXPERIMENTALCCX140-B 15 mg twice daily (N=10)
Placebo (Group A)PLACEBO_COMPARATOR -
CCX140-B (Group B)EXPERIMENTAL -
CCX140-B (Group C)EXPERIMENTAL -
Active study medication (Group B)EXPERIMENTALCCX140-B
PlaceboPLACEBO_COMPARATOR -
Active controlACTIVE_COMPARATOR -
Active Study Medication (Group C)EXPERIMENTALCCX140-B
Active Study Medication (Group D)EXPERIMENTALCCX140-B

Interventions

NameTypeDescription
PlaceboOTHERThree placebo tablets, taken twice daily (BID), per os, for 84 days (12 weeks)
CCX140-BDRUGOne 5 mg CCX140-B tablet and 2 placebo tablets in the morning; 3 placebo tablets in the evening; per os, for 84 days.
pioglitazoneDRUGpioglitazone 30 mg tablet once daily
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 75 Years
SexALL
Healthy VolunteersNo
Study Sites37

Inclusion Criteria: 1. Male or female subjects aged 18-75 2. UPCR ≥ 1 g protein/g creatinine (or at 113 mg.mmol) at screening 3. Diagnosis of FSGS based on renal biopsy or high risk genetic variant 4. Diagnosis of one of primary FSGS based on characteristic histopathology, medical history and clini...

Countries:United StatesAustraliaCanadaFranceItalyNew ZealandPolandUnited KingdomBelgiumCzechiaGermanyHungaryNetherlands
Unlock Eligibility Criteria

Competitive Landscape -Diabetic Nephropathy 12 trials

Top 3 of 6 competitors

CompanyTickerTrialsLead PhaseDrugs
Regeneron Pharmaceuticals, Inc.REGN1PHASE2ALN-ANG3, Evinacumab
Novartis AG Sponsored ADRNVS1PHASE2Atrasentan
ProKidney Corp. Class APROK2 - Rilparencel
Unlock Competitive Intelligence

Frequently asked questions about CCX140-B

What is CCX140-B used for?

CCX140-B is an investigational small molecule being studied for the treatment of focal segmental glomerulosclerosis (FSGS), diabetic nephropathy, and type 2 diabetes mellitus. It has been evaluated in Phase 2 clinical trials for these conditions, but it is not approved and remains in clinical development.

Who makes CCX140-B?

CCX140-B is being developed by Amgen Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol AMGN. The drug is an investigational small molecule that has completed Phase 2 trials for kidney-related and metabolic conditions.

What phase is CCX140-B in?

CCX140-B is in Phase 2 clinical development. It has completed four Phase 2 trials, including studies in type 2 diabetes mellitus, diabetic nephropathy, and focal segmental glomerulosclerosis. The drug is investigational and has not been approved by regulatory authorities.

What clinical trials has CCX140-B been in?

CCX140-B has completed four Phase 2 trials: NCT01028963 in type 2 diabetes mellitus, NCT01440257 and NCT01447147 in diabetic nephropathy with type 2 diabetes, and NCT03536754 in focal segmental glomerulosclerosis. These trials were randomized, double-blind, and placebo-controlled, enrolling a total of 352 participants.

Is CCX140-B the same as any other drug?

No alternative names for CCX140-B have been disclosed. The drug is identified solely by its investigational code CCX140-B in clinical trial registries and by its developer, Amgen Inc.

Explore more on BiopharmaWatch

Amgen Inc. (AMGN)Pipeline, catalysts, financials, insiders and newsBiotech disease mapWho is developing what in each indication, and how crowded it isFDA calendarUpcoming PDUFA dates, AdComs and approval oddsPDUFA calendarEvery scheduled FDA decision date, month by monthHistorical FDA calendarPast decisions and how the stock moved on eachCatalyst SyncUpcoming readouts and decisions, screened by runway and phaseBiotech stock screenerFilter by clinical phase, cash runway and market capDrugs A to ZEvery drug page starting with CCompanies A to ZEvery biotech and pharma company we track